Today (11/30) Moderna announced their plans to seek emergency use authorization from the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccine candidate that reported a 94.1% efficacy rate. The study, that evaluated over 30,000 U.S participants, has not yielded any safety hazards. Moderna is also looking to expand their emergency use authorization to Europe.
Learn more here.
More on: News Regulatory